


Appl. No. 10/689,388
 Atty. Docket No. 8717MR2
 Amdt. dated November 9, 2005
 Response to Telephone Conference of November 2, 2005
 Customer No. 27752

AMENDMENTS

IN THE CLAIMS

1. (Previously presented) A method for providing pain relief to humans or higher mammals, said method comprising the step of administering to a human or higher mammal an effective amount of a compound, including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, said compound having the formula:



wherein R is:

- a) $-O[CH_2]_kR^3$; or
- b) $-NR^{4a}R^{4b}$;

R^3 is substituted or unsubstituted C_1 - C_4 alkyl, substituted or unsubstituted hydrocarbyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or alkylenearyl, substituted or unsubstituted heteroaryl or alkyleneheteroaryl; the index k is from 0 to 5;

R^{4a} and R^{4b} are each independently:

- a) hydrogen; or
- b) $-[C(R^{5a}R^{5b})]_mR^6$;

each R^{5a} and R^{5b} are independently hydrogen, $-OR^7$, $-N(R^7)_2$, $-CO_2R^7$, $-CON(R^7)_2$; C_1 - C_4 linear, branched, or cyclic alkyl, and mixtures thereof; R^6 is hydrogen, $-OR^7$, $-N(R^7)_2$, $-CO_2R^7$, $-CON(R^7)_2$; substituted or unsubstituted C_1 - C_4 alkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R^7 is hydrogen, a water-soluble cation, C_1 - C_4 alkyl, or substituted or unsubstituted aryl; the index m is from 0 to 5;

R^1 is:

- a) substituted or unsubstituted aryl; or
- b) substituted or unsubstituted heteroaryl;

Appl. No. 10/689,388
 Atty. Docket No. 8717MR2
 Amdt. dated November 9, 2005
 Response to Telephone Conference of November 2, 2005
 Customer No. 27752


each R^2 unit is independently selected from the group consisting of:

- a) hydrogen;
- b) $-(CH_2)_jO(CH_2)_nR^8$;
- c) $-(CH_2)_jNR^{9a}R^{9b}$;
- d) $-(CH_2)_jCO_2R^{10}$;
- e) $-(CH_2)_jOCO_2R^{10}$;
- f) $-(CH_2)_jCON(R^{10})_2$;
- g) $-(CH_2)_jOCON(R^{10})_2$;
- h) two R^2 units can be taken together to form a carbonyl unit;
- i) and mixtures thereof;


R^8 , R^{9a} , R^{9b} , and R^{10} are each independently hydrogen, C_1 - C_4 alkyl, and mixtures thereof; R^{9a} and R^{9b} can be taken together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; two R^{10} units can be taken together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; j is an index from 0 to 5, n is an index from 0 to 5; Z is O, S, NR^{11} , or NOR^{11} ; R^{11} is hydrogen or C_1 - C_4 alkyl.

2. (Previously presented) A method according to Claim 1 wherein said compound is selected from scaffolds having the formula:

i)




ii)



Appl. No. 10/689,388
 Atty. Docket No. 8717MR2
 Amdt. dated November 9, 2005
 Response to Telephone Conference of November 2, 2005
 Customer No. 27752


iii)




3. (Previously presented) A method according to Claim 2 wherein R is a unit having the formula $-OR^3$ wherein R^3 is selected from the group consisting of phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,6-difluorophenyl, 2-cyanophenyl, 3-cyanophenyl, 2-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-methylphenyl, 4-methylphenyl, 2,4-dimethylphenyl, 3-N-acetylaminophenyl, 2-methoxyphenyl, 4-methoxyphenyl, and 3-benzo[1,3]dioxol-5-yl; R^1 is 4-fluorophenyl.

4. (Previously presented) A method according to Claim 2 wherein R is a unit selected form:

i)



ii)




wherein R^6 is selected from the group consisting of hydrogen, methyl, ethyl, vinyl, cyclopropyl, cyclohexyl, methoxymethyl, methoxyethyl, 1-hydroxy-1-methylethyl, carboxy, phenyl, 4-fluorophenyl, 2-aminophenyl, 2-methylphenyl, 4-methylphenyl, 4-methoxyphenyl, 4-(propanesulfonyl)phenyl, 3-benzo[1,3]dioxol-5-yl, pyridin-2-yl, pyridin-3-yl; R^8 is hydrogen or C_1 - C_4 alkyl, the indices j and n are each equal to 0.

5. (Previously presented) A method according to Claim 4 wherein R^{9a} and R^{9b} are each independently hydrogen or C_1 - C_4 alkyl, the index j is equal to 0.

Appl. No. 10/689,388
 Atty. Docket No. 8717MR2
 Amdt. dated November 9, 2005
 Response to Telephone Conference of November 2, 2005
 Customer No. 27752

6. (Previously presented) A method according to Claim 5 wherein R^{9a} and R^{9b} are taken together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms, the index j is equal to 0.
7. (Previously presented) A method according to Claim 6 wherein said ring is morpholin-1-yl, piperidin-1-yl, or piperazin-1-yl.
8. (Previously presented) A method according to Claim 1 wherein said compound has the formula:



wherein each R^2 unit is independently selected from the group consisting of:

- hydrogen;
- $-(CH_2)_jO(CH_2)_nR^8$;
- $-(CH_2)_jNR^{9a}R^{9b}$;
- $-(CH_2)_jCO_2R^{10}$;
- $-(CH_2)_jOCO_2R^{10}$;
- $-(CH_2)_jCON(R^{10})_2$;
- $-(CH_2)_jOCON(R^{10})_2$;
- two R^2 units can be taken together to form a carbonyl unit;
- and mixtures thereof;

R^8 , R^{9a} , R^{9b} , and R^{10} are each independently hydrogen, C_1 - C_4 alkyl, and mixtures thereof; R^{9a} and R^{9b} can be taken together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; two R^{10} units can be take together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; j is an index from 0 to 5, n is an index from 0 to 5;

Appl. No. 10/689,388
Atty. Docket No. 8717MR2
Amdt. dated November 9, 2005
Response to Telephone Conference of November 2, 2005
Customer No. 27752

R³ is substituted or unsubstituted C₁-C₄ alkyl, substituted or unsubstituted hydrocarbyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or alkylenearyl, substituted or unsubstituted heteroaryl or alkyleneheteroaryl; the index k is from 0 to 5.

9. (Previously presented) A method according to Claim 1 wherein said compound is selected from the group consisting of:

2-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;
N-(3-{4-[2-(4-Fluoro-phenyl)-3-oxo-6,7-dihydro-3H,5H-pyrazolo[1,2-a]pyrazol-1-yl]-pyrimidin-2-yloxy}-phenyl)-acetamide;
2-(4-Fluorophenyl)-3-[2-(2,4-dimethylphenoxy)pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;
2-(2,4-Difluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;
2-(4-Fluorophenyl)-3-[2-(4-fluorophenoxy)pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;
2-(4-Fluorophenyl)-3-[2-(2,6-difluorophenoxy)pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;
2-(4-Fluorophenyl)-3-[2-(2-fluorophenoxy)pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one; and
2-(4-Fluorophenyl)-3-[2-(3-fluorophenoxy)pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;
2-(4-Fluorophenyl)-3-[2-(S)-(1-phenylethylamino)pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one;
2-(4-Fluorophenyl)-3-[2-(N'-methyl-N'-phenylhydrazino)-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one;
(R)-{4-[2-(4-Fluorophenyl)-3-oxo-6,7-dihydro-3H,5H-pyrazolo[1,2-a]pyrazol-1-yl]-pyrimidin-2-ylamino}-phenylacetic acid methyl ester;
2-(4-Fluorophenyl)-3-(2-benzylaminopyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one;

Appl. No. 10/689,388
Atty. Docket No. 8717MR2
Amdt. dated November 9, 2005
Response to Telephone Conference of November 2, 2005
Customer No. 27752

2-(4-Fluorophenyl)-3-[2-(1-(*S*)-methylethylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[2-(allylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-{2-[1-(*S*)-(4-methylphenyl)ethylamino]pyrimidin-4-yl}-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[2-(1-(*S*)-cyclohexyl-ethylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[2-(1-(*R*)-phenylethylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[2-(*tert*-butylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[2-(2-hydroxy-1,2-dimethylpropylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[(2-cyclopropylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[(2-cyclopropylmethyl)aminopyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[(2-methoxyethylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[(2-methoxyethylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-{2-[1-(*S*)-(4-fluorophenyl)ethylamino]pyrimidin-4-yl}-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-{2-[(pyridin-3-yl)methyl]amino]pyrimidin-4-yl}-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-6-morpholin-4-yl-3-[2-(4-fluorophenoxy)-pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

6-Dimethylamino-2-(4-fluorophenyl)-3-[2-(1-phenylethylamino)-pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-6-hydroxy-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

Appl. No. 10/689,388
Atty. Docket No. 8717MR2
Amdt. dated November 9, 2005
Response to Telephone Conference of November 2, 2005
Customer No. 27752

Morpholine-4-carboxylic acid 6-(4-fluorophenyl)-5-oxo-7-(2-phenoxy-pyrimidin-4-yl)-2,3-dihydro-1*H*,5*H*-pyrazolo[1,2-*a*]pyrazol-2-yl ester;
2-(4-Fluorophenyl)-6-methoxy-3-[2-(2-(*S*)-methoxy-1-methylethylamino)-pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;
2-(4-Fluorophenyl)-6-methylene-3-[2-(2-(*S*)-phenyl-1-methylethylamino)-pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;
2-(4-Fluorophenyl)-6-hydroxy-6-hydroxymethyl-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;
2-(3-trifluoromethylphenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;
2-(4-fluorophenyl)-3-(2-(6-aminopyrimidin-4-yloxy)pyrimidin-4-yl)-6,7-dihydro-5*H*-pyrazolo-[1,2-*a*]pyrazol-1-one;
2-(4-fluorophenyl)-3-[2-(3-fluorophenoxy)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo-[1,2-*a*]pyrazol-1-one;
2-(4-fluorophenyl)-3-[2-(2,4-dimethylphenoxy)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo-[1,2-*a*]pyrazol-1-one;
2-(2,4-difluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5*H*-pyrazolo-[1,2-*a*]pyrazol-1-one;
2-(4-fluorophenyl)-3-[2-(4-chlorophenoxy)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo-[1,2-*a*]pyrazol-1-one;
2-(4-Fluorophenyl)-3-{2-[1-(*R,S*)-(4-fluorophenyl)ethylamino]pyrimidin-4-yl}-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;
2-{4-[2-(4-Fluorophenyl)-3-oxo-6,7-dihydro-3*H*,5*H*-pyrazolo[1,2-*a*]pyrazol-1-yl]-pyrimidin-2-ylamino}-propionic acid;
2-{4-[2-(4-Fluorophenyl)-3-oxo-6,7-dihydro-3*H*,5*H*-pyrazolo[1,2-*a*]pyrazol-1-yl]-pyrimidin-2-ylamino}-*N,N*-dimethyl propionamide;
2-(4-Fluorophenyl)-3-(2-([1,3,4]thiadiazol-2-ylamino)pyrimidin-4-yl)-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;
2-(4-Fluorophenyl)-3-{2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;
2-(4-Fluorophenyl)-3-[(2-methoxypropylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

Appl. No. 10/689,388
Atty. Docket No. 8717MR2
Amdt. dated November 9, 2005
Response to Telephone Conference of November 2, 2005
Customer No. 27752

2-(4-Fluorophenyl)-3-{2-[(furan-2-ylmethyl)amino]pyrimidin-4-yl}-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one;
2-(4-Fluorophenyl)-3-{2-[(3-benzo[1,3]dioxol-5-yl)amino]pyrimidin-4-yl}-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one;
2-(4-Fluorophenyl)-3-{2-[(1-(propane-1-sulfonyl)piperidin-4-ylamino]pyrimidin-4-yl}-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one; and
2-(4-Fluorophenyl)-3-{2-(4-methoxybenzylamino)amino]pyrimidin-4-yl}-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one.

10 – 12 (Cancelled)

13. (Previously presented) A pharmaceutical composition comprising:

- a) an effective amount of one or more bicyclic pyrazolones including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, said compound selected from the group consisting of:
- 2-(4-fluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;
N-(3-{4-[2-(4-Fluoro-phenyl)-3-oxo-6,7-dihydro-3H,5H-pyrazolo[1,2-a]pyrazol-1-yl]-pyrimidin-2-yloxy}-phenyl)-acetamide;
2-(4-Fluorophenyl)-3-[2-(2,4-dimethylphenoxy)pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;
2-(2,4-Difluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;
2-(4-Fluorophenyl)-3-[2-(4-fluorophenoxy)pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;
2-(4-Fluorophenyl)-3-[2-(2,6-difluorophenoxy)pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;
2-(4-Fluorophenyl)-3-[2-(2-fluorophenoxy)pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one; and
2-(4-Fluorophenyl)-3-[2-(3-fluorophenoxy)pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;

Appl. No. 10/689,388
Atty. Docket No. 8717MR2
Amdt. dated November 9, 2005
Response to Telephone Conference of November 2, 2005
Customer No. 27752

2-(4-Fluorophenyl)-3-[2-(*S*)-(1-phenylethylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[2-(*N'*-methyl-*N'*-phenylhydrazino)-pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

(*R*)-{4-[2-(4-Fluorophenyl)-3-oxo-6,7-dihydro-3*H*,5*H*-pyrazolo[1,2-*a*]pyrazol-1-yl]-pyrimidin-2-ylamino}-phenylacetic acid methyl ester;

2-(4-Fluorophenyl)-3-(2-benzylaminopyrimidin-4-yl)-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[2-(1-(*S*)-methylethylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[2-(allylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-{2-[1-(*S*)-(4-methylphenyl)ethylamino]pyrimidin-4-yl}-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[2-(1-(*S*)-cyclohexyl-ethylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[2-(1-(*R*)-phenylethylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[2-(*tert*-butylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[2-(2-hydroxy-1,2-dimethylpropylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[(2-cyclopropylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[(2-cyclopropylmethyl)aminopyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[(2-methoxyethylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-[(2-methoxyethylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

2-(4-Fluorophenyl)-3-{2-[1-(*S*)-(4-fluorophenyl)ethylamino]pyrimidin-4-yl}-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;

Appl. No. 10/689,388
Atty. Docket No. 8717MR2
Amdt. dated November 9, 2005
Response to Telephone Conference of November 2, 2005
Customer No. 27752

2-(4-Fluorophenyl)-3-{2-[(pyridin-3-ylmethyl)amino]pyrimidin-4-yl}-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one;

2-(4-Fluorophenyl)-6-morpholin-4-yl-3-[2-(4-fluorophenoxy)-pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one;

6-Dimethylamino-2-(4-fluorophenyl)-3-[2-(1-phenylethylamino)-pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one;

2-(4-Fluorophenyl)-6-hydroxy-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one;

Morpholine-4-carboxylic acid 6-(4-fluorophenyl)-5-oxo-7-(2-phenoxy-pyrimidin-4-yl)-2,3-dihydro-1H,5H-pyrazolo[1,2-a]pyrazol-2-yl ester;

2-(4-Fluorophenyl)-6-methoxy-3-[2-(2-(S)-methoxy-1-methylethylamino)-pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one;

2-(4-Fluorophenyl)-6-methylene-3-[2-(2-(S)-phenyl-1-methylethylamino)-pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one;

2-(4-Fluorophenyl)-6-hydroxy-6-hydroxymethyl-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one;

2-(3-trifluoromethylphenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;

2-(4-fluorophenyl)-3-(2-(6-aminopyrimidin-4-yloxy)pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;

2-(4-fluorophenyl)-3-[2-(3-fluorophenoxy)pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;

2-(4-fluorophenyl)-3-[2-(2,4-dimethylphenoxy)pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;

2-(2,4-difluorophenyl)-3-(2-phenoxy-pyrimidin-4-yl)-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;

2-(4-fluorophenyl)-3-[2-(4-chlorophenoxy)pyrimidin-4-yl]-6,7-dihydro-5H-pyrazolo-[1,2-a]pyrazol-1-one;

2-(4-Fluorophenyl)-3-{2-[1-(R,S)-(4-fluorophenyl)ethylamino]pyrimidin-4-yl}-6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-one;

Appl. No. 10/689,388

Atty. Docket No. 8717MR2

Amdt. dated November 9, 2005


Response to Telephonic Conference of November 2, 2005

Customer No. 27752

- 2-{4-[2-(4-Fluorophenyl)-3-oxo-6,7-dihydro-3*H*,5*H*-pyrazolo[1,2-*a*]pyrazol-1-yl]-pyrimidin-2-ylamino}-propionic acid;
- 2-{4-[2-(4-Fluorophenyl)-3-oxo-6,7-dihydro-3*H*,5*H*-pyrazolo[1,2-*a*]pyrazol-1-yl]-pyrimidin-2-ylamino}-*N,N*-dimethyl propionamide;
- 2-(4-Fluorophenyl)-3-(2-([1,3,4]thiadiazol-2-ylamino)pyrimidin-4-yl)-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;
- 2-(4-Fluorophenyl)-3-{2-[(pyridin-2-ylmethyl)amino]pyrimidin-4-yl}-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;
- 2-(4-Fluorophenyl)-3-[(2-methoxypropylamino)pyrimidin-4-yl]-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;
- 2-(4-Fluorophenyl)-3-{2-[(furan-2-ylmethyl)amino]pyrimidin-4-yl}-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;
- 2-(4-Fluorophenyl)-3-{2-[(3-benzo[1,3]dioxol-5-yl)amino]pyrimidin-4-yl}-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one;
- 2-(4-Fluorophenyl)-3-{2-[(1-(propane-1-sulfonyl)piperidin-4-ylamino]pyrimidin-4-yl}-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one; and
- 2-(4-Fluorophenyl)-3-{2-(4-methoxybenzylamino)amino]pyrimidin-4-yl}-6,7-dihydro-5*H*-pyrazolo[1,2-*a*]pyrazol-1-one; and
- b) one or more pharmaceutically acceptable excipients.

14. (Previously presented) A pharmaceutical composition comprising:

- a) an effective amount of one or more bicyclic pyrazolones including all enantiomeric and diastereomeric forms and pharmaceutically acceptable salts thereof, said compound having the formula:



Appl. No. 10/689,388
 Atty. Docket No. 8717MR2
 Amdt. dated November 9, 2005
 Response to Telephone Conference of November 2, 2005
 Customer No. 27752

wherein R is:

- a) $-\text{O}[\text{CH}_2]_k\text{R}^3$; or
- b) $-\text{NR}^{4a}\text{R}^{4b}$;

R^3 is substituted or unsubstituted C_1 - C_4 alkyl, substituted or unsubstituted hydrocarbyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted aryl or alkylenearyl, substituted or unsubstituted heteroaryl or alkyleneheteroaryl; the index k is from 0 to 5;

R^{4a} and R^{4b} are each independently:

- a) hydrogen; or
- b) $-\text{C}(\text{R}^{5a}\text{R}^{5b})_m\text{R}^6$;

each R^{5a} and R^{5b} are independently hydrogen, or C_1 - C_4 linear, branched, or cyclic alkyl, and mixtures thereof; R^6 is hydrogen, $-\text{OR}^7$, $-\text{N}(\text{R}^7)_2$, $-\text{CO}_2\text{R}^7$, $-\text{CON}(\text{R}^7)_2$; substituted or unsubstituted C_1 - C_4 alkyl, substituted or unsubstituted heterocyclic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R^7 is hydrogen, a water-soluble cation, C_1 - C_4 alkyl, or substituted or unsubstituted aryl; the index m is from 0 to 5;

R^1 is:

- a) substituted or unsubstituted aryl; or
- b) substituted or unsubstituted heteroaryl;

each R^2 unit is independently selected from the group consisting of:

- a) hydrogen;
- b) $-(\text{CH}_2)_j\text{O}(\text{CH}_2)_n\text{R}^8$;
- c) $-(\text{CH}_2)_j\text{NR}^{9a}\text{R}^{9b}$;
- d) $-(\text{CH}_2)_j\text{CO}_2\text{R}^{10}$;
- e) $-(\text{CH}_2)_j\text{OCO}_2\text{R}^{10}$;
- f) $-(\text{CH}_2)_j\text{CON}(\text{R}^{10})_2$;
- g) $-(\text{CH}_2)_j\text{OCON}(\text{R}^{10})_2$;
- h) two R^2 units can be taken together to form a carbonyl unit;
- i) and mixtures thereof;

R^8 , R^{9a} , R^{9b} , and R^{10} are each independently hydrogen, C_1 - C_4 alkyl, and mixtures thereof; R^{9a} and R^{9b} can be taken together to form a carbocyclic or heterocyclic ring comprising from 3 to 7 atoms; two R^{10} units can be take

Appl. No. 10/689,388
Atty. Docket No. 8717MR2
Amdt. dated November 9, 2005
Response to Telephone Conference of November 2, 2005
Customer No. 27752

together to form a carbocyclic or heterocyclic ring comprising from 3 to 7

atoms; j is an index from 0 to 5, n is an index from 0 to 5;

Z is O, S, NR¹¹, or NOR¹¹; R¹¹ is hydrogen or C₁-C₄ alkyl;

- b) an effective amount of one or more compounds having pain relief properties;
- and
- b) one or more pharmaceutically acceptable excipients.

15. (Previously presented) A composition according to Claim 14 wherein said compound having pain relief properties are selected from the group consisting of acetaminophen, aspirin, difunisal, dipyron, ibuprofen, naproxen, fenoprofen, fenbufen, ketoprofen, flurbiprofen, indomethacin, ketorolac, diclofenac, floctafenine, piroxicam, celecoxib, and rofecoxib.

16. (Previously presented) A composition according to Claim 14 wherein said compound having pain relief properties are selected from the group consisting of oxycodone, pethidine/meperidine, methadone, levorphanol, hydromorphone, and buprenorphine.